In the last trading session, 1.2 million Black Diamond Therapeutics Inc (NASDAQ:BDTX) shares changed hands as the company’s beta touched 2.65. With the company’s per share price at $2.11 changed hands at $0.16 or 8.21% during last session, the market valuation stood at $119.98M. BDTX’s last price was a discount, traded about -219.91% off its 52-week high of $6.75. The share price had its 52-week low at $1.20, which suggests the last value was 43.13% up since then.
Analysts gave the Black Diamond Therapeutics Inc (BDTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BDTX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Black Diamond Therapeutics Inc’s EPS for the current quarter is expected to be -0.22.
Black Diamond Therapeutics Inc (NASDAQ:BDTX) trade information
Instantly BDTX was in green as seen at the end of in last trading. With action 20.57%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -1.40%, with the 5-day performance at 20.57% in the green. However, in the 30-day time frame, Black Diamond Therapeutics Inc (NASDAQ:BDTX) is 46.53% up.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 84.93% from its current market value. According to analyst projections, BDTX’s forecast low is 11 with 20 as the target high. To hit the forecast high, the stock’s price needs a -847.87% plunge from its current level, while the stock would need to soar -421.33% for it to hit the projected low.
Black Diamond Therapeutics Inc (BDTX) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -5.22%. The 2025 estimates are for Black Diamond Therapeutics Inc earnings to increase by 88.39%, but the outlook for the next 5-year period is at 2.33% per year.
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s Major holders
BELLEVUE GROUP AG holds the second largest percentage of outstanding shares, with 16.4409% or 8.52 million shares worth $39.69 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were T. Rowe Price Small-Cap Value Fund, Inc. and T. Rowe Price Small-Cap Stock Fund, Inc. With 2.42 shares estimated at $5.12 million under it, the former controlled 4.26% of total outstanding shares. On the other hand, T. Rowe Price Small-Cap Stock Fund, Inc. held about 4.17% of the shares, roughly 2.37 shares worth around $5.01 million.
